Life sciences start-up support powered by NGI
Starting up a company is tricky in any sector. It is particularly tough in one that is as fast moving as life sciences. The Netherlands Genomics Initiative fully recognises this difficulty and has put together a coherent support programme for life sciences starters by initiating a series of activities and partnering with existing start-up programmes.
Find out how we can help you!
LifeSciences@work brings start-up support activities, former- and future participants and experts community together. The support programme covers aspects such as coaching/training, financial support and networking activities.
I have an idea for a new business.
What should I do next?
Get coaching!Read more »
I need to improve my business skills.
What are my options?
Get training!Read more »
I have a (draft) business plan.
How do I get my business started?
Get financing!Read more »
I have just started a company.
Where can I get answers to day-to-day issues?
Get connected!Read more »
- 04 April 2013 Waste2Chemical, a pioneer in developing high added value chemicals from waste streams, raised first round investment from Horizon3 en Dutch Greentech Fund. Read more »
- 27 February 2013 Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels. Read more »
- 25 February 2013 The young Leiden-based biotech company Mimetas has closed an agreement with a regional development company from the state of Maryland, USA. Biohealth Innovation Inc., in which regional governments, universities and companies collaborate, will assist in setting up a US branch to find customers and business partners for Mimetas in the USA. Read more »
- 29 January 2013 Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD). Read more »
- 14 January 2013 OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell culture-based screening platform to profile bispecific antibodies designed by Merus for the treatment of cancer. Read more »